(Reuters) - A Maryland judge denied a request to temporarily restrain Human Genome Sciences from taking measures to fend off GlaxoSmithKline's hostile $2.6 billion takeover bid, according to a court notification. Duane Howell, a Human Genome shareholder, had filed a lawsuit against the U.S. biotechnology company's board and requested that the court invalidate Human Genome's "poison pill" stockholder rights plan designed to ward off GlaxoSmithKline. ...{br}{br}View the Entire Article{br}